Company Overview and News

Core Exploration has Chinese backing to transform into lithium producer

Core Exploration Ltd (ASX:CXO) is developing one of Australia’s highest grade lithium resources at the Grants deposit within the Finniss Lithium Project near Darwin.
Upvote Downvote

Make Your Own High-Risk/High-Reward Lithium ETF

2018-01-09 seekingalpha
These lithium stocks have the potential to provide a much better return on investment than the Global X Lithium & Battery Tech ETF.
Upvote Downvote

Core Exploration’ shares rise on drilling wide lithium intersections at Bynoe

Core Exploration Ltd (ASX:CXO) has received drilling assays confirming the presence of wide, high grade spodumene at the BP33 pegmatite at its Bynoe lithium project near Darwin.
Upvote Downvote

Core Resources acquires NT lithium project from Liontown

Core Resources has finalised its acquisition of the Bynoe lithium project in the Northern Territory from Liontown Resources.
Upvote Downvote

Core Exploration combines two major lithium projects in the Northern Territory

Core Exploration Ltd (ASX:CXO) has completed the acquisition of the Bynoe lithium project from Liontown Resources Ltd (ASX:LTR) for $1.5 million in cash and an 8.2% stake in Core’s share capital.
Upvote Downvote

Liontown Resources has lithium results on the table from the newly acquired Buldania

Liontown Resources Ltd (ASX:LTR) recently acquired two projects, Buldania and Norcott, prospective for pegmatite-hosted lithium mineralisation.
Upvote Downvote

Liontown Resources acquires two lithium projects in the Eastern Goldfields

Liontown Resources Limited (ASX:LTR) has acquired two highly prospective lithium projects, Buldania and Norcott, located in the Eastern Goldfields of Western Australia.
Upvote Downvote

Liontown Resources calls halt in shares for asset update

Liontown Resources Ltd (ASX:LTR) has been granted a trading halt this morning by the ASX, pending details of an asset disposal.
Upvote Downvote

Liontown Resources discovers lithium zone in Tanzania

Liontown Resources (ASX:LTR) has identified high-grade, spodumene-related lithium mineralisation at its Mohanga Lithium-Tantalum Project in Tanzania.
Upvote Downvote

White Cliff Minerals spins drill on hunt for lithium

White Cliff Minerals (ASX:WCN) has commenced drilling at its Lake Percy Lithium Project in Western Australia.
Upvote Downvote

Liontown Resources begins drilling for lithium at Kathleen Valley

Liontown Resources (ASX:LTR) has commenced the maiden reverse circulation drilling program at its Kathleen Valley Lithium-Tantalum Project, located in the Eastern Goldfields of Western Australia.
Upvote Downvote

White Cliff Minerals finds gold anomalies at Comet Well

White Cliff Minerals (ASX:WCN) has identified gold in-soil anomalies at the Comet Well prospect located within the Merolia gold project located in Laverton near Western Australia.
Upvote Downvote

Liontown Resources in capital raising

The halt will remain in place until the opening of trade on Wednesday, 25th January 2017, or earlier if an announcement is made to the market.
Upvote Downvote

White Cliff Minerals granted tenement adjacent to lithium discovery

White Cliff Minerals (ASX:WCN) has been granted a 20 square kilometre tenement immediately north of its Lake Percy joint venture tenement located in Western Australia where a lithium anomaly was recently discovered.
Upvote Downvote

Korab Resources Ltd receives Rum Jungle tenement grant offer

The lease area is located 70 kilometres south of Darwin near the town of Batchelor in the Northern Territory.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...